


## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Pier  
Serial No: 09/405,735  
Filed: September 24, 1999  
For: METHODS AND PRODUCTS FOR TREATING PSEUDOMONAS INFECTION  
Examiner: Unassigned  
Art Unit: 1646



## CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on the 18th day of January, 2000.

Kim Ray-Akeeli

Assistant Commissioner for Patents  
Washington, D.C. 20231

## PRELIMINARY AMENDMENT

Sir:

Before calculating the filing fee, please amend claims 9-13, 22-25, 34, 52-53, and 60-61 as follows:

B1  
9. (Amended) The method of claim[s] 1 [-8] wherein the subject has a condition predisposing the subject to a *Pseudomonal* infection.

10. (Amended) The method of claim[s] 1 [-8] wherein the subject has a *Pseudomonal* infection.

11. (Amended) The method of claim[s] 1 [-8] wherein the subject has a defective cystic fibrosis transmembrane conductance regulator gene.

12. (Amended) The method of claim[s] 1 [-8] wherein the polysaccharide is administered systemically to the subject.

13. (Amended) The method of claim[s] 1 [-8] wherein the polysaccharide is administered by inhalation to the subject.

B<sup>2</sup> 22. (Amended) The pharmaceutical preparation of claim[s] 14 [-21] wherein the pharmaceutical preparation is sterile.

23. (Amended) The pharmaceutical preparation of claim[s] 14 [-21] wherein the pharmaceutical preparation is formulated in a unit dosage in an amount effective for treating *Pseudomonal* infection.

24. (Amended) The pharmaceutical preparation of claim[s] 14 [-21] wherein the pharmaceutical preparation is formulated as an aerosol for inhalation.

25. (Amended) The pharmaceutical preparation of claim[s] 14 [-21] wherein the pharmaceutical preparation is formulated as an injectable preparation.

B<sup>3</sup> 34. (Amended) The composition of matter of claim[s] 26 [-33] wherein the lipid has the following structural formula:  $\text{CH}_3(\text{CH}_2)_n\text{COOH}$  wherein  $n=1-50$ .

B<sup>4</sup> 52. (Amended) The method of claims 44 [-51] wherein the bioactive agent is covalently coupled to the polysaccharide.

53. (Amended) The method of claim[s] 44 [-51] wherein the bioactive agent is contained in a liposome comprising a lipid biocompatible with a human subject, and wherein the polysaccharide is covalently coupled to the lipid.

B<sup>5</sup> 60. (Amended) The composition of claim[s] 54 [-59] wherein the anti-*Pseudomonal* drug is an antibiotic.

61. (Amended) The composition of claim[s] 54 [-59] wherein the anti-*Pseudomonal* drug is selected from the group consisting of Amifloxacin; Amifloxacin Mesylate; Amikacin; Amikacin Sulfate; Aminosalicyclic acid; Aminosalicylate sodium; Azlocillin; Azlocillin Sodium; Bacampicillin Hydrochloride; Carbenicillin Disodium; Carbenicillin Indanyl Sodium; Carbenicillin Phenyl Sodium; Carbenicillin Potassium; Carumonam Sodium; Cefaclor; Cefadroxil; Cefamandole; Cefamandole Nafate; Cefamandole Sodium; Cefaparolet; Cefatrizine; Cefazaflur Sodium; Cefazolin; Cefazolin Sodium; Cefbuperazone; Cefdinir; Cefepime; Cefepime Hydrochloride; Cefetecol; Cefixime; Cefmenoxime Hydrochloride; Cefmetazole; Cefmetazole Sodium; Cefonicid Monosodium; Cefonicid Sodium; Cefoperazone Sodium; Ceforanide; Cefotaxime Sodium; Cefotetan; Cefotetan Disodium; Cefotiam Hydrochloride; Cefoxitin; Cefoxitin Sodium; Cefpimizole; Cefpimizole Sodium; Cefpiramide; Cefpiramide Sodium; Cefpirome Sulfate; Cefpodoxime Proxetil; Cefprozil; Cefroxadine; Cefsulodin Sodium; Ceftazidime; Ceftibuten; Ceftizoxime Sodium; Ceftriaxone Sodium; Cefuroxime;

65  
Cefuroxime Axetil; Cefuroxime Pivoxetil; Cefuroxime Sodium; Cephacetrile Sodium;  
Cephalexin; Cephalexin Hydrochloride; Cephaloglycin; Cephaloridine; Cephalothin Sodium;  
Cephapirin Sodium; Cephradine; Cetocycline Hydrochloride; Cetophenicol; Chlortetracycline  
Bisulfate ; Chlortetracycline Hydrochloride ; Ciprofloxacin; Ciprofloxacin Hydrochloride;  
Colistin Sulfate; Coumermycin; Coumermycin Sodium; Doxycycline; Doxycycline Calcium;  
Doxycycline Fosfatex; Doxycycline Hyclate; Droxacin Sodium; Enoxacin; Epicillin;  
Epitetracycline Hydrochloride; Imipenem; Kanamycin Sulfate; Meclocycline; Minocycline;  
Minocycline Hydrochloride; Nafcillin Sodium; Norfloxacin; Ofloxacin; Oxytetracycline;  
Oxytetracycline Calcium; Piperacillin Sodium; Piperacillin Sodium; Tetracycline; Tetracycline  
Hydrochloride ; Tetracycline Phosphate Complex; Ticarcillin Cresyl Sodium; Ticarcillin  
Disodium; Ticarcillin Monosodium; Tobramycin, and Tobramycin Sulfate.

Respectfully submitted,



Helen C. Lockhart  
Reg. No. 39,248  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, MA 02210-2211  
(617)720-3500

Docket No.B0801/7155  
January 18, 2000  
X1/18/00